Reports
Sale
Acute Lymphoblastic Leukemia Therapeutics Market Size, Share: By Type: B-cell Acute Lymphoblastic Leukemia, C-cell Acute Lymphoblastic Leukemia; By Treatment: Chemotherapy, Radiation Therapy, Others; By Patient Type; By Route of Administration; By Distribution Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Acute Lymphoblastic Leukemia Therapeutics Market Outlook
The acute lymphoblastic leukemia therapeutics market size was valued at USD 2.79 billion in 2023, driven by increasing demand of personalised treatment across the major markets. The market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032, with the values likely to rise from USD 2.79 billion in 2024 to USD 4.19 billion by 2032.
Acute Lymphoblastic Leukemia Therapeutics Market Overview
Acute lymphoblastic leukemia (ALL) is a cancer of blood and bone marrow, specifically affecting the lymphocytes (white blood cells). It is the most common type of cancer in children but can also occur in adults. It accounts for 74% of the overall pediatric leukemia cases. The risk of developing the disease gradually declines until the mid-20s and begins to rise after a person attains the age of 50. ALL affects approximately 4 out of every 10 adults. While most cases affect children, the death rate is significantly higher in adults (about 4 out of 5).
Acute lymphoblastic leukemia therapeutics market demand is driven by the rising incidence of the disease in recent years. As per data released by the American Cancer Society in 2023, around 6,540 new ALL cases are expected to affect the United States population, out of which 3,660 cases are expected in males and 2,880 cases in females. The deaths associated with the disease are projected to be around 1,390 (700 in males and 690 in females). While it is not a common cancer, the average person’s lifetime risk of developing the disease is 1 in 1,000. The male community is more susceptible to this category of tumor than the females.
-therapeutics-market.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Surge in Combination Therapies for Personalized Treatment
The acute lymphoblastic leukemia therapeutics market share is expected to be dominated by combination therapies, owing to their efficacy in reducing tumor progression and minimizing other side effects associated with the condition. In January 2023, the results of a clinical trial revealed that blinatumomab (Blincyto), when combined with chemotherapy, showed 83% improvement in the survival rate as opposed to those who were subjected to chemotherapy alone (65%).
Growth in Immunotherapy and Targeted Therapies to Drive the Market Growth
With the rising popularity of targeted therapy to treat cancer, a class of tyrosine kinase inhibitors (TKI) has been found effective in treating newly diagnosed ALL in patients. One such example is Takeda Pharmaceutical’s Ponatinib , which is currently under phase I trial for pediatric Ph+ acute lymphoblastic leukemia. It prevents tumor progression by blocking BCR-ABL protein.
Asparaginase therapies are also considered as critical treatment alternative for acute lymphoblastic leukemia. Currently, the FDA has approved five asparaginase therapies. Owing to its reduced immunogenicity compared to native E. coli preparations and satisfactory pharmacokinetic profile, pegaspargase is used as the firsthand asparaginase therapeutic option. To meet the rising acute lymphoblastic leukemia therapeutics market demand, regulatory authorities around the world are approving new drug therapies for treatment.
In July 2023, the European Medicines Agency (EMA) showed a positive opinion on the authorization of marketing Jazz Pharmaceutical’s JZP458 (a recombinant Erwinia asparaginase or crisantaspase) in the region. L -asparaginase lowers the serum levels of L-asparagine, resulting in cell death. This is because the enzyme is present in the human body and not naturally synthesized by the leukemic cells. It is expected to be used as a constituent of a multi-agent chemotherapeutic routine for the treatment of acute lymphoblastic leukemia in adults as well as children who have developed silent inactivation or hypersensitivity to E. coli derived asparaginase.
Emphasis on Cancer Recurrence
Preventing recurrence of acute lymphoblastic leukemia is a key area of investigation amongst scientists. Hence, there is an emphasis on pairing standard leukemia treatments with new class of drugs to prevent relapse. In addition, immune checkpoint blockade that disrupts the pathway used by cancer cells to evade the immune system are also being evaluated in clinical trials. The search for new technologies and alternatives, coupled with improving technical advancements, is expected to support the acute lymphoblastic leukemia therapeutics market size in the forecast period.
-therapeutics-market-by-therapy-type.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Acute Lymphoblastic Leukemia Therapeutics Market Segmentation
Market Breakup by Type
- Bone Marrow Transplant
- B-cell Acute Lymphoblastic Leukemia
- C-cell Acute Lymphoblastic Leukemia
Market Breakup by Treatment
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Immunotherapy
- Others
Market Breakup by Patient Type
- Adult
- Pediatric
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
-therapeutics-market-by-region.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Acute Lymphoblastic Leukemia Therapeutics Market Regional Analysis
The United States, with a well-established medical and research infrastructure is expected to lead the acute lymphoblastic leukemia therapeutics market share in upcoming years. The market size is further fueled by the inauguration of research centers with a vision to encourage research and innovation. In September 2023, Cincinnati Children's Hospital launched advanced leukemia therapies and research center that aims to integrate more research and clinical programs for improved patient outcomes.
Acute Lymphoblastic Leukemia Therapeutics Market: Competitor Landscape
In December 2023, Theseus Pharmaceuticals entered a merger agreement with Concentra Biosciences wherein the company will acquire Theseus Pharmaceuticals for a stock price of USD 3.90 and USD 4.05 in cash. The merger is focused on improving the lives of cancer patients with discovery, commercialization, and development of transformative targeted therapies.
In March 2023, Pfizer acquired Seagen for USD 43 billion to develop antibody drug candidates, a pioneer in the cancer class drugs. Such acquisitions are a clear indicator that the market for cancer therapeutics is anticipated to witness substantial growth in the forecast period.
The key features of the acute lymphoblastic leukemia therapeutics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Eisai Co Ltd
- GlaxoSmithKline plc.
- Celegene Corporation
- Bristol Myer Squibb Company
- Pfizer Inc.
- Sanofi SA
- Genmab A/S
- Erytech Pharma
- Takeda Pharmaceutical Company Limited
- OBI Pharma
- Astellas Pharma Inc.
- Medexus Pharma, Inc.
- Kiadis Pharma
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Patient Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Acute Lymphoblastic Leukemia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Acute Lymphoblastic Leukemia Epidemiology Analysis – 7 Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
5.3.1 Germany Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
5.3.2 France Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
5.3.3 Italy Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
5.3.4 Spain Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
5.4 Japan Acute Lymphoblastic Leukemia Epidemiology Forecast (2017-2032)
6 Acute Lymphoblastic Leukemia Therapeutics Market Overview – Major Markets
6.1 Acute Lymphoblastic Leukemia Therapeutics Market Historical Value (2017-2023)
6.2 Acute Lymphoblastic Leukemia Therapeutics Market Forecast Value (2024-2032)
7 Acute Lymphoblastic Leukemia Therapeutics Market Landscape – Major Markets
7.1 Acute Lymphoblastic Leukemia Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Acute Lymphoblastic Leukemia Therapeutics Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment
7.2.3 Analysis by Route of Administration
8 Acute Lymphoblastic Leukemia Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Acute Lymphoblastic Leukemia Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Acute Lymphoblastic Leukemia Therapeutics Market Segmentation – Major Markets
11.1 Acute Lymphoblastic Leukemia Therapeutics Market by Type
11.1.1 Market Overview
11.1.2 B-cell Acute Lymphoblastic Leukemia
11.1.3 C-cell Acute Lymphoblastic Leukemia
11.2 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
11.2.1 Market Overview
11.2.2 Chemotherapy
11.2.3 Radiation Therapy
11.2.4 Bone Marrow Transplant
11.2.5 Targeted Therapy
11.2.6 Immunotherapy
11.2.7 Others
11.3 Acute Lymphoblastic Leukemia Therapeutics Market by Patient Type
11.3.1 Market Overview
11.3.2 Adult
11.3.3 Pediatric
11.4 Acute Lymphoblastic Leukemia Therapeutics Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.5 Acute Lymphoblastic Leukemia Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.5.5 Others
11.6 Acute Lymphoblastic Leukemia Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Acute Lymphoblastic Leukemia Therapeutics Market
12.1 Acute Lymphoblastic Leukemia Therapeutics Market Historical Value (2017-2023)
12.2 Acute Lymphoblastic Leukemia Therapeutics Market Forecast Value (2024-2032)
12.3 Acute Lymphoblastic Leukemia Therapeutics Market by Type
12.4 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
13 EU-4 and United Kingdom Acute Lymphoblastic Leukemia Therapeutics Market
13.1 Acute Lymphoblastic Leukemia Therapeutics Market Historical Value (2017-2023)
13.2 Acute Lymphoblastic Leukemia Therapeutics Market Forecast Value (2024-2032)
13.3 Germany Acute Lymphoblastic Leukemia Therapeutics Market Overview
13.3.1 Acute Lymphoblastic Leukemia Therapeutics Market by Type
13.3.2 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
13.4 France Acute Lymphoblastic Leukemia Therapeutics Market Overview
13.4.1 Acute Lymphoblastic Leukemia Therapeutics Market by Type
13.4.2 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
13.5 Italy Acute Lymphoblastic Leukemia Therapeutics Market Overview
13.5.1 Acute Lymphoblastic Leukemia Therapeutics Market by Type
13.5.2 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
13.6 Spain Acute Lymphoblastic Leukemia Therapeutics Market Overview
13.6.1 Acute Lymphoblastic Leukemia Therapeutics Market by Type
13.6.2 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
13.7 United Kingdom Acute Lymphoblastic Leukemia Therapeutics Market Overview
13.7.1 Acute Lymphoblastic Leukemia Therapeutics Market by Type
13.7.2 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
14 Japan Acute Lymphoblastic Leukemia Therapeutics Market
14.1 Acute Lymphoblastic Leukemia Therapeutics Market Historical Value (2017-2023)
14.2 Acute Lymphoblastic Leukemia Therapeutics Market Forecast Value (2024-2032)
14.3 Acute Lymphoblastic Leukemia Therapeutics Market by Type
14.4 Acute Lymphoblastic Leukemia Therapeutics Market by Treatment
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Novartis AG
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 F. Hoffmann-La Roche Ltd
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Eisai Co Ltd
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 GlaxoSmithKline plc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Celegene Corporation
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Bristol Myer Squibb Company
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Pfizer Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Sanofi SA
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Genmab A/S
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Erytech Pharma
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Takeda Pharmaceutical Company Limited
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 OBI Pharma
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Astellas Pharma Inc.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Medexus Pharma, Inc.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Kiadis Pharma
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Acute Lymphoblastic Leukemia Therapeutics Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.79 billion in 2023, driven by the increasing demand for personalised treatment across the major markets.
The market is anticipated to grow at a CAGR of 4.6% during the forecast period of 2024-2032, likely to reach a market value of USD 4.19 billion by 2032.
The market demand is driven by the increasing incidence of the disease in adults as well as children in recent years, along with surge in investments on research and development and rising partnerships amongst vital healthcare companies.
The major market trend revolves around using innovative alternatives such as immune checkpoint blockades and combining standard leukemia treatments with new class of drugs to prevent cancer recurrence.
Based on patient types, the market is divided into adults and paediatrics.
Based on disease type, the market is divided into B-cell acute lymphoblastic leukemia and C-cell acute lymphoblastic leukemia.
Chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy, among others are common technologies available in the market.
Major distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy, among others.
The routes of administration can be oral and parenteral.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co Ltd., GlaxoSmithKline plc., Celegene Corporation, Bristol Myer Squibb Company, Pfizer Inc., Sanofi SA, Genmab A/S, Erytech Pharma, Takeda Pharmaceutical Company Limited, OBI Pharma, Astellas Pharma Inc., Medexus Pharma, Inc., and Kiadis Pharma.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER